T1	Participants 150 400	we tested in patients with metabolic syndrome whether allopurinol through decreasing oxidative stress improves endothelial function, and ameliorates inflammatory state represented by markers of myeloperoxidase, C-reactive protein (CRP) and fibrinogen
T2	Participants 804 930	placebo groups demonstrated no differences in terms of clinical characteristics, endothelial function and inflammatory markers
